Ken Griffin Neurocrine Biosciences Inc Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 2,049,075 shares of NBIX stock, worth $264 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
2,049,075
Previous 19,500
10408.08%
Holding current value
$264 Million
Previous $2.16 Million
11845.64%
% of portfolio
0.05%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
101MCall Options Held
282KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.83 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$718 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$576 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$398 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...